Blog

The latest thoughts from Medicines Law & Policy partners.

WIPO and pharma industry launch global medicines patent database

On 25 September, the World Intellectual Property Organisation (WIPO) in collaboration with the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) launched the Patent...

Commission report on competition enforcement in the pharmaceutical sector

Guest author Jacquelyn D. Veraldi is Assistant Professor of European Law at the University of Groningen. Guest author Tais A. Ruiz Palacios is a...

Wrapping up 2024: Noteworthy events in medicines law and policy around the globe

Welcome to Medicines Law & Policy’s  end of the year blog, our highly biased annual overview of memorable medicines law and policy events. January At the...

Socially Responsible Licensing of Medical Technologies

GENEVA, SWITZERLAND: On 31 October, the World Trade Organization (WTO), the World Health Organization (WHO) and the World Intellectual Property Organization (WIPO) held their...

Pharmaceutical Pricing Hostages

Ireland seems to be the stage of some of the most bizarre pharmaceutical company behaviour these days. This month, the pharmaceutical company CSL Behring...

The European Commission’s compulsory licensing proposals are sensible but do not go far enough

An earlier version of this comment was published in Barron's on 21 July 2023. A Spanish translation of it is also available from El...

The elephant in the room at the WHO Executive Board

The World Health Organization (WHO) Director-General, Dr Tedros Adhanom Ghebreyesus spoke harshly about the lack of Covid-19 vaccines in developing countries at the opening of...

European Pharmaceutical Legislation Needs Exceptions to Data and Market Exclusivity to Protect European Patients...

On 11 May 2018, US President Trump announced his plans to lower drug prices in America. Under the banner "American Patients First" he outlined...

WTO Members discuss proposal to suspend certain intellectual property protection during the Covid-19 crisis

An earlier version of this comment was published by The Wire on 13 October 2020. On 2 October, India and South Africa sent a proposal...

FDA approval of injectable lenacapavir for Pre-Exposure Prophylaxis (PrEP) opens the road to ending...

On 18th June 2025, the US Food and Drug Administration (FDA) approved the use of long-acting antiretroviral medicine lenacapavir (LEN-LA), for the prevention of...